Abstract
Characterizing changes in the small cell lung cancer (SCLC) patient population and SCLC treatment landscape is essential for understanding drivers of outcomes among those patients. Four checkpoint inhibitors (CPIs) were approved for SCLC in 2018 (nivolumab), 2019 (atezolizumab and pembrolizumab), and 2020 (durvalumab), but SCLC was subsequently removed from the nivolumab and pembrolizumab labels in 2020 in 2021, respectively. Durvalumab and atezolizumab are approved for use in the first line (1L) SCLC setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
